Stevanato Group's commitment against coronavirus pandemic
Piombino Dese (PD), March 19th, 2020 - In the current situation that sees an international mobilization to fight the Coronavirus pandemic, Stevanato Group is strongly committed to safeguarding the health and safety of its employees and stakeholders. Stevanato Group - as leader in the production of glass containers for the pharmaceutical industry and supplier of integrated solutions for medical devices - is guaranteeing primary packaging supplies to support patient care worldwide, and offering its concrete help to support organizations that operate in the health sector in Veneto.
Since the early stages of the spread of the epidemic, the company has implemented strict precautionary measures provided by national and regional regulations on personal and workplace hygiene, as well as on the organization of working life at its plants. It has adopted measures to avoid crowding, maximizing the use of agile working and remote communication systems, allowing access to external personnel only if in compliance with current legislation, and suspending business trips.
In Italy, in compliance with the latest government regulations, Stevanato Group has implemented a safety protocol shared with company union representatives and Workers' Representatives for Safety, which, among other measures, has restricted the access to production and common areas, applying the measure of a minimum interpersonal distance. A joint protocol verification committee has also been set up, which is currently evaluating further measures for the protection of personnel.
A dedicated task force has also been created to coordinate all activities aimed at guaranteeing the health and safety of employees and the continuity of glass containers supply to pharmaceutical companies. The Group plays a key role in the fight against COVID-19 as a supplier of containers for vaccines under-development and medical treatments for patients.
Moreover, confirming its strong commitment to the territory in which it was born, Stevanato Group has decided to donate an initial amount of 500,000 euros to support a multitude of healthcare structures operating in the provinces of Padua, Venice, and Treviso.
It will be used for donations and for the purchase of medical and personal protection equipment and devices to support the current unprecedented effort of doctors, nurses, and all hospital staff.
“For over 70 years, the role of Stevanato Group has been to support pharmaceutical companies in patient care all over the world. In this moment of international emergency that puts a strain on all the medical structures in the territory, it is our duty to give our contribution to the community in which we live and work, " comments Franco Stevanato, CEO of Stevanato Group. “We have worked tirelessly to protect the employees in our plants and secure supplies to our customers. Now we want to give concrete support to the local structures that are daily facing many difficulties against the spread of the virus, aware of our role and of our contribution in facing and overcoming this moment of emergency."
Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group is able to offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership.
Released March 19, 2020